IRIS Accounts Production v24.3.2.46 10094069 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false 8823 14957 8823 14957 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh100940692023-03-31100940692024-03-31100940692023-04-012024-03-31100940692022-03-31100940692022-04-012023-03-31100940692023-03-3110094069ns15:EnglandWales2023-04-012024-03-3110094069ns14:PoundSterling2023-04-012024-03-3110094069ns10:Director12023-04-012024-03-3110094069ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3110094069ns10:SmallEntities2023-04-012024-03-3110094069ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3110094069ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3110094069ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3110094069ns10:FullAccounts2023-04-012024-03-311009406912023-04-012024-03-3110094069ns10:Director2422022-03-3110094069ns10:Director2422023-04-012024-03-3110094069ns10:Director2422022-04-012023-03-3110094069ns10:Director2422024-03-3110094069ns10:Director22023-04-012024-03-3110094069ns10:Director32023-04-012024-03-3110094069ns10:Director42023-04-012024-03-3110094069ns10:Director52023-04-012024-03-3110094069ns10:RegisteredOffice2023-04-012024-03-3110094069ns5:CurrentFinancialInstruments2024-03-3110094069ns5:CurrentFinancialInstruments2023-03-3110094069ns5:ShareCapital2024-03-3110094069ns5:ShareCapital2023-03-3110094069ns5:RetainedEarningsAccumulatedLosses2024-03-3110094069ns5:RetainedEarningsAccumulatedLosses2023-03-3110094069ns5:NetGoodwill2023-04-012024-03-3110094069ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3110094069ns5:FurnitureFittings2023-04-012024-03-3110094069ns5:MotorVehicles2023-04-012024-03-3110094069ns5:ComputerEquipment2023-04-012024-03-3110094069ns5:NetGoodwill2023-03-3110094069ns5:NetGoodwill2024-03-3110094069ns5:NetGoodwill2023-03-3110094069ns5:FurnitureFittings2023-03-3110094069ns5:MotorVehicles2023-03-3110094069ns5:ComputerEquipment2023-03-3110094069ns5:FurnitureFittings2024-03-3110094069ns5:MotorVehicles2024-03-3110094069ns5:ComputerEquipment2024-03-3110094069ns5:FurnitureFittings2023-03-3110094069ns5:MotorVehicles2023-03-3110094069ns5:ComputerEquipment2023-03-3110094069ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3110094069ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-31100940691ns10:Director12023-03-31100940691ns10:Director12022-03-31100940691ns10:Director12023-04-012024-03-31100940691ns10:Director12022-04-012023-03-31100940691ns10:Director12024-03-31100940691ns10:Director12023-03-31
REGISTERED NUMBER: 10094069 (England and Wales)








Unaudited Financial Statements

for the Year Ended

31 March 2024

for

KFKC Medical Limited

KFKC Medical Limited (Registered number: 10094069)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


KFKC Medical Limited

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Dr K F K Chan
Mrs J K L Lee
Ms J K F Wong
M K C Chan
H F L Tsang





REGISTERED OFFICE: Church Court
Stourbridge Road
Halesowen
West Midlands
B63 3TT





REGISTERED NUMBER: 10094069 (England and Wales)





ACCOUNTANTS: HSP Nicklin Limited
Church Court
Stourbridge Road
Halesowen
West Midlands
B63 3TT

KFKC Medical Limited (Registered number: 10094069)

Balance Sheet
31 March 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 34,306 45,643
34,306 45,643

CURRENT ASSETS
Stocks 200 200
Debtors 6 85,129 102,068
Cash at bank 315,391 239,180
400,720 341,448
CREDITORS
Amounts falling due within one year 7 23,505 17,021
NET CURRENT ASSETS 377,215 324,427
TOTAL ASSETS LESS CURRENT
LIABILITIES

411,521

370,070

CAPITAL AND RESERVES
Called up share capital 104 104
Retained earnings 411,417 369,966
SHAREHOLDERS' FUNDS 411,521 370,070

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 January 2025 and were signed on its behalf by:





Dr K F K Chan - Director


KFKC Medical Limited (Registered number: 10094069)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

KFKC Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents invoiced sales of services except in respect to service contracts where turnover is recognised when the company obtains the right to consideration.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2016, is being amortised evenly over its estimated useful life of three years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 20% on cost
Motor vehicles - 20% on cost
Computer equipment - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2023 - 6 ) .

KFKC Medical Limited (Registered number: 10094069)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 10,000
AMORTISATION
At 1 April 2023
and 31 March 2024 10,000
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

5. TANGIBLE FIXED ASSETS
Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 April 2023 130 49,150 8,292 57,572
Additions - - 787 787
At 31 March 2024 130 49,150 9,079 58,359
DEPRECIATION
At 1 April 2023 26 9,830 2,073 11,929
Charge for year 26 9,830 2,268 12,124
At 31 March 2024 52 19,660 4,341 24,053
NET BOOK VALUE
At 31 March 2024 78 29,490 4,738 34,306
At 31 March 2023 104 39,320 6,219 45,643

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 70,172 98,973
Other debtors 14,957 3,095
85,129 102,068

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security 17,262 1,783
Other creditors 6,243 15,238
23,505 17,021

KFKC Medical Limited (Registered number: 10094069)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 March 2024 and 31 March 2023:

2024 2023
£    £   
Dr K F K Chan and Mrs J K L Lee
Balance outstanding at start of year - 8,823
Amounts advanced 14,957 -
Amounts repaid - (8,823 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 14,957 -

9. RELATED PARTY DISCLOSURES

The amount due to the directors at the year end was £nil (2023: £6,381).